BioCentury
ARTICLE | Company News

Alexza, Ferrer deal

July 20, 2015 7:00 AM UTC

The companies added the Middle East and North Africa region, Korea, the Philippines and Thailand to a 2011 deal granting Grupo Ferrer exclusive rights to commercialize Adasuve loxapine. Grupo Ferrer now has rights in the additional territories and Europe, Latin America and the Commonwealth of Independent States. Alexza will also suspend its manufacturing obligations and grant Ferrer an option to manufacture Adasuve and additional Staccato products for territories outside of the U.S., Canada, Taiwan and China, including Hong Kong and Macau. The option expires on Dec. 31.

Alexza is transferring its postapproval activities for Adasuve in the EU to Ferrer, including clinical studies and pharmacovigilance. Alexza agreed to waive undisclosed milestone payments for the first commercial sales of Adasuve in Russia, Brazil and Turkey in exchange for Ferrer’s added responsibilities (see BioCentury, Oct. 10, 2011; March 12, 2012 & Nov. 17, 2014). ...